行情

ZLAB

ZLAB

再鼎医药
NASDAQ

实时行情|Nasdaq Last Sale

38.93
0.00
0.00%
盘后: 38.93 0 0.00% 16:35 11/15 EST
开盘
39.21
昨收
38.93
最高
39.22
最低
38.48
成交量
10.07万
成交额
--
52周最高
40.37
52周最低
16.55
市值
25.77亿
市盈率(TTM)
-14.9863
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZLAB 新闻

  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.2天前
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.3天前
  • Buy These 2 Stocks to Access China's Huge Healthcare Market
  • MotleyFool.com.11/06 12:22
  • Zai Lab Announces Upcoming Presentations at November Conferences
  • GlobeNewswire.10/30 12:30

更多

所属板块

生物技术和医学研究
+1.35%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

ZLAB 简况

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
展开

Webull提供Zai Lab Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。